Tag: Takeda
Takeda strengthens patient offering in India via availability of Kynteles
Takeda Pharma has introduced innovative Gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD) and Ulcerative Colitis and Crohn's Disease. Kynteles is likely to benefit patients with a low risk of serious or opportunistic infections like Tuberculosis...................
Takeda India contributes ₹1.2 Crore to COVID-19 PM Cares Fund
The contribution to the PM Cares Fund aims to support patients and the Government to contain the spread of the disease.................
World Hemophilia Day: Takeda India stands united for hemophilia patients
While approximately 21,000 hemophilic patients are registered in India, the ongoing government support, standards of care have improved in the country......................
Takeda appoints new country head for India
Seasoned biopharmaceutical leader with over 17 years of experience across geographies, Koki Sato to lead Takeda’s business in India, ensuring patient access to highly innovative medicines.......................
Takeda initiates development of a plasma-derived therapy for COVID-19
Exploring the potential to repurpose marketed products and molecules, the company is developing Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat infected, high-risk individuals with COVID-19...................
Takeda appoints Dr Mahender Nayak as new Area Head for India
Proven leader with more than 20 years of experience in the biopharmaceutical industry, Dr Mahender Nayak will continue to increase patient access to Takeda’s portfolio of highly innovative medicines..................
Takeda expands India portfolio of rare disease therapies
The company has launched Enzyme Replacement Therapy bouquet for Lysosomal Storage Disorders (LSD), Idursulfase for Hunter Syndrome, Velaglucerase Alpha for Gaucher Disease and Agalsidase Alfa for Fabry Disease..........................
Takeda announces Andrey Potapov as ICMEA Area Head
Potapov’s appointment follows Takeda’s recent acquisition of Shire Pharmaceuticals – enabling Takeda to become a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan...............